AB198288

重组Anti-Apolipoprotein CI/Apo-CI抗体[EPR16813]

Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813]

RabMAb
Recombinant
了解详情

Be the first to review this product! Submit a review

(12 Publications)

Rabbit Recombinant Monoclonal Apolipoprotein CI/Apo-CI antibody. Suitable for IP, WB, IHC-P and reacts with Human samples. Cited in 12 publications.

查看别名

Apolipoprotein C-I, Apo-CI, ApoC-I, Apolipoprotein C1, APOC1

5 Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813] (AB198288)

IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813] (AB198288)

Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling Apolipoprotein CI/Apo-CI with ab198288 at 1/1600 dilution followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution. Cytoplasm staining on Human liver tissue is observed. Counter stained with Hematoxylin.
Negative control : Used PBS instead of primary ab.

Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Supplier Data

Immunoprecipitation - Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813] (AB198288)

Immunoprecipitation analysis of Human plasma whole cell extract labeling Apolipoprotein CI/Apo-CI using ab198288 at 1/40 dilution (Lane 2).
Lane 3 : IP using Rabbit monoclonal IgG (ab172730) instead of ab198288 in Human plasma whole cell extract.
Lane 1 : Input : 10 μg Human plasma whole cell extract.
Subsequent WB detection was performed using ab198288 at 1/1000 dilution.
An Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1500 was used as secondary antibody.

All lanes:

Immunoprecipitation - Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813] (ab198288)

Predicted band size: 9 kDa

Observed band size: 6.6 kDa

false

Supplier Data

Western blot - Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813] (AB198288)

Blocking/dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813] (ab198288) at 1/5000 dilution

All lanes:

Human plasma lysate at 20 µg

Secondary

All lanes:

Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

Predicted band size: 9 kDa

Observed band size: 6.6 kDa

false

Supplier Data

Western blot - Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813] (AB198288)

Blocking/dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813] (ab198288) at 1/1000 dilution

All lanes:

Human fetal liver lysate at 20 µg

Secondary

All lanes:

Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

Predicted band size: 9 kDa

Observed band size: 6.6 kDa

false

Supplier Data

Western blot - Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813] (AB198288)

Blocking/dilution buffer : 5% NFDM/TBST. We suggest treating cells with BFA which inhibits protein secretion.

All lanes:

Western blot - Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813] (ab198288) at 1/1000 dilution

Lanes 1 and 3:

Untreated HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg

Lanes 2 and 4:

HepG2 (Human hepatocellular carcinoma epithelial cell) treated with 300ng/ml BFA for 48 hours whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 9 kDa

Observed band size: 88 kDa

false

Exposure time: 180s

不同偶联物与剂型 (1)

Carrier free

Anti-Apolipoprotein CI/Apo-CI antibody [EPR16813] - BSA and Azide free

关键信息

宿主种属

Rabbit

克隆

Monoclonal

克隆号

EPR16813

亚型

IgG

不含载体蛋白

反应种属

Human

应用

WB, IHC-P, IP

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

反应性数据

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/40", "IP-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "1/800", "ICCIF-species-notes": "", "FlowCytIntra-species-checked": "notRecommended", "FlowCytIntra-species-dilution-info": "1/80", "FlowCytIntra-species-notes": "<a href='/products/primary-antibodies/rabbit-igg-monoclonal-epr25a-isotype-control-ab172730'>ab172730</a> - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/800", "IHCP-species-notes": "" } } }

style

left-column

产品详情

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

性能和储存信息

形式

Liquid

纯化工艺

Affinity purification Protein A

存储溶液

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

运输条件

Blue Ice

分装信息

Upon delivery aliquot

储存信息

Avoid freeze / thaw cycle

style

left-column

补充信息

This supplementary information is collated from multiple sources and compiled automatically.

Apolipoprotein CI (Apo-CI) plays a mechanical role in lipid metabolism where it acts as an inhibitor of lipoprotein lipase and hepatic lipase hindering lipolytic activity. It is also known as 'apo 250' and 'apo atv20' with a molecular mass of approximately 6.6 kDa. Apo-CI is primarily expressed in the liver and secreted into the plasma where it associates with high-density lipoproteins (HDL) and very low-density lipoproteins (VLDL).

Biological function summary

Apo-CI influences plasma triglyceride levels and cholesterol homeostasis. It plays a role in lipid transport and metabolism by modulating the binding of other apolipoproteins such as apo A-IV and interfering with the binding of lipoproteins to their receptors. Apo-CI is part of a complex of apolipoproteins that regulate lipid metabolism working in tandem to balance lipid and cholesterol levels in the body.

Pathways

Apo-CI is actively involved in the lipoprotein metabolism pathway and cholesterol efflux pathway. These pathways are important in maintaining lipid balance and cardiovascular health. Apo-CI is related to other apolipoproteins within these pathways such as apo E and apo A-I. Its function in modulating lipoprotein receptor interactions aligns with the broader mechanisms of these pathways in lipid and cholesterol regulation.

Elevated levels of Apo-CI are associated with hyperlipidemia and cardiovascular disease. These conditions may result from its inhibitory effects on lipase activity leading to increased triglyceride levels. Apo-CI's interaction with other apolipoproteins such as apo B and apo E is linked to its role in the pathogenesis of these disorders. Understanding Apo-CI's involvement in these diseases can guide therapeutic strategies aimed at regulating its expression and function.

style

left-column

style

left-column

产品实验方案

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

靶点信息

Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein.

See full target information APOC1

style

left-column

文献 (12)

Recent publications for all applications. Explore the full list and refine your search

Nature medicine 31:1604-1616 PubMed40050704

2025

Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer's disease.

Applications

Unspecified application

Species

Unspecified reactive species

Lynn van Olst,Brooke Simonton,Alex J Edwards,Anne V Forsyth,Jake Boles,Pouya Jamshidi,Thomas Watson,Nate Shepard,Talia Krainc,Benney Mr Argue,Ziyang Zhang,Joshua Kuruvilla,Lily Camp,Mengwei Li,Hang Xu,Jeanette L Norman,Joshua Cahan,Robert Vassar,Jinmiao Chen,Rudolph J Castellani,James Ar Nicoll,Delphine Boche,David Gate

Experimental and therapeutic medicine 25:163 PubMed36911382

2023

APOC1 promotes the progression of osteosarcoma by binding to MTCH2.

Applications

Unspecified application

Species

Unspecified reactive species

Renjie Li,Huixian He,Xinxin He

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 10:e2204565 PubMed36709495

2023

Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Esophageal Squamous Cell Carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Yongxu Jia,Baifeng Zhang,Chunyang Zhang,Dora Lai-Wan Kwong,Zhiwei Chang,Shanshan Li,Zehua Wang,Huiqiong Han,Jing Li,Yali Zhong,Xin Sui,Li Fu,Xinyuan Guan,Yanru Qin

Cancers 13: PubMed34298684

2021

The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Aubrey L Miller,Patrick L Garcia,Samuel C Fehling,Tracy L Gamblin,Rebecca B Vance,Leona N Council,Dongquan Chen,Eddy S Yang,Robert C A M van Waardenburg,Karina J Yoon

Aging 13:14968-14988 PubMed34081622

2021

Construction of a novel mRNA-miRNA-lncRNA network and identification of potential regulatory axis associated with prognosis in colorectal cancer liver metastases.

Applications

Unspecified application

Species

Unspecified reactive species

Chen Lu,Xiagang Luo,Cheng Xing,Yonghuan Mao,Yuting Xu,Wenjie Gao,Wulin Wang,Tian Zhan,Guoguang Wang,Zhengxia Liu,Chunzhao Yu

Frontiers in oncology 10:1436 PubMed32974161

2020

Apolipoprotein C1 (APOC1): A Novel Diagnostic and Prognostic Biomarker for Clear Cell Renal Cell Carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Yankang Cui,Chenkui Miao,Chao Hou,Zengjun Wang,Bianjiang Liu

Annals of translational medicine 7:380 PubMed31555694

2019

Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Jie Yi,Liwen Ren,Jie Wu,Wan Li,Xiangjin Zheng,Guanhua Du,Jinhua Wang

Cancer management and research 11:4917-4930 PubMed31213910

2019

Apolipoprotein C1 (APOC1) promotes tumor progression via MAPK signaling pathways in colorectal cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Hui Ren,Zhihui Chen,Liang Yang,Weixin Xiong,Hong Yang,Kaiwu Xu,Ertao Zhai,Li Ding,Yulong He,Xingming Song

Frontiers in neuroscience 12:847 PubMed30487733

2018

Altered High Density Lipoprotein Composition in Behavioral Variant Frontotemporal Dementia.

Applications

Unspecified application

Species

Unspecified reactive species

Woojin Scott Kim,Ying He,Katherine Phan,Rebekah M Ahmed,Kerry-Anne Rye,Olivier Piguet,John R Hodges,Glenda M Halliday

Virology 524:1-9 PubMed30130702

2018

Characterization of apolipoprotein C1 in hepatitis C virus infection and morphogenesis.

Applications

Unspecified application

Species

Unspecified reactive species

Han Zhang,Luhua Qiao,Guangxiang Luo

View all publications

style

left-column

style

left-column

style

right-column

Abcam Product Promise

我们致力于为您的研究提供高质量的试剂，为您科研的每一步提供支持。若我们的产品未能达到预期性能，我们向您提供 Abcam Product Promise 保障。

详情请参阅我们的条款与条件。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

重组Anti-Apolipoprotein CI/Apo-CI抗体[EPR16813]